Trading Update

EpiStem Holdings plc
31 July 2007

EPISTEM HOLDINGS PLC

TRADING UPDATE - JULY 2007

The Board Of Directors of EpiStem Holdings Plc confirm that the results for the
Company for the year ended 30th June 2007 are in line with management
expectations with a year on year revenue growth of approximately 50% being
achieved. Further details of the financial performance for the year will be
announced in October 2007 (to be confirmed).

The Board of Directors is also pleased to announce the appointment of Roger
Lloyd as a non-executive Director of the Company. Dr Lloyd, aged 59, brings a
wealth of experience to EpiStem, having only recently stood down as Executive
Director, Global Licensing at AstraZeneca plc. In this capacity, he headed up
the deal making team responsible for the acquisitions by AstraZeneca of
Cambridge Antibody Technologies plc and KuDOS Pharmaceuticals Limited as well as
other strategically important transactions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange